Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 49 citing articles:

The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Salvatore Petta, Giovanni Targher, Stefano Romeo, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1526-1536
Open Access | Times Cited: 56
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 26
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
Reddemma Sandireddy, Suganya Sakthivel, Priyanka Gupta, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 19
Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021
Hirayuki Enomoto, Norio Akuta, Hayato Hikita, et al.
Hepatology Research (2024) Vol. 54, Iss. 8, pp. 763-772
Open Access | Times Cited: 15
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 4
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
Phuc Le, Moosa Tatar, Srinivasan Dasarathy, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2454707-e2454707
Open Access | Times Cited: 3
Modulating the microbiome in chronic liver diseases- current evidence on the role of fecal microbiota transplantation
Srishti Saha, Bernd Schnabl
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 1
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot
Eda Kaya, Wing‐Kin Syn, Paul Manka
Current Opinion in Gastroenterology (2025)
Closed Access | Times Cited: 1
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 7
Identification and Treatment of Alcohol Use Disorder
Paul Haber
New England Journal of Medicine (2025) Vol. 392, Iss. 3, pp. 258-266
Closed Access
Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
Brian Lam, Jessica Bartholomew, Sherona Bau, et al.
Journal of Clinical Gastroenterology (2025)
Closed Access
Liver diseases: epidemiology, causes, trends and predictions
Can Gan, Yuan Yuan, Haiyuan Shen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Expanding Indications in Transplant Oncology
Erlind Allkushi, Chase J. Wehrle, Jaekeun Kim, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 773-773
Open Access
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access
Lean MASLD and Cardiovascular Disease: A Review
Nachum Lebovics, Gabriel Heering, William H. Frishman, et al.
Cardiology in Review (2025)
Closed Access
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review
Consolato Sergi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8462-8462
Open Access | Times Cited: 4
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance
Angelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Metabolism (2024), pp. 156080-156080
Open Access | Times Cited: 4
Hepatic Estrogen Receptor Alpha Overexpression Protects Against Hepatic Insulin Resistance and MASLD
Ester S. Alves, Jéssica Denielle Matos dos SANTOS, Alessandra G. Cruz, et al.
Pathophysiology (2025) Vol. 32, Iss. 1, pp. 1-1
Open Access
Risk of hepatic decompensation or HCC is similar in patients with ALD- and MASLD-cirrhosis: A population-based cohort study
Joost Boeckmans, Linnea Widman, Ying Shang, et al.
European Journal of Internal Medicine (2025)
Open Access
Differential candidate characteristics associated with increasing ALD and MASH among liver transplant listings in the US
Ashwani K. Singal, Winston Dunn, Robert J. Wong, et al.
Digestive and Liver Disease (2025)
Closed Access
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis
Sheena Bhushan, Aalam Sohal, Mazen Noureddin, et al.
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Challenges in the management of MetALD after liver transplantation
M. Cucco, Chiara Becchetti, Miki Scaravaglio, et al.
Metabolism and Target Organ Damage (2025) Vol. 5, Iss. 1
Open Access
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Exploring Systemic Impacts and Innovative Therapies
Parag Jain, Akanksha Jain, Rohitas Deshmukh, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102584-102584
Closed Access
Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults
Guannan Zong, Wangjia Mao, Ming Wen, et al.
Annals of Hepatology (2024), pp. 101583-101583
Open Access | Times Cited: 3
Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region
Saleh A. Alqahtani, Yusuf Yılmaz, Mohamed El‐Kassas, et al.
Annals of Hepatology (2024), pp. 101569-101569
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top